Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT05059522
Active, not recruiting Phase 3

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522 · tracked via the Priya Life Science USA tracker
Sponsor
Pfizer
Phase
Phase 3
Started
2021-09-29
Last updated
2026-10-20

Condition(s) studied

Advanced MalignanciesNSCLCOvarian CancerUrothelial CancerSolid Tumors

Investigational drug(s) / intervention(s)

Avelumab →LorlatanibTalazoparib →Pemetrexed →Axitinib →CMP 001 →Utomilumab →PF04518600

Avelumab: oral

Lorlatanib: oral

Talazoparib: oral

Pemetrexed: IV (intravenous) infusion

Axitinib: oral

CMP 001: IT (intratumoral) or SC (subcutaneous)

Utomilumab: IV infusion

PF04518600: IV infusion

Study summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study. 2. Participants must agree to follow the reproductive criteria. 3. Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures. Exclusion Criteria: 1. Female participants who are pregnant or breastfeeding. 2. Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Primary outcome measure(s)

  • Number of participants with adverse events leading to permanent discontinuation of study intervention — Baseline up to approximately 5 years
  • Number serious adverse events reported for all participants — Baseline up to approximately 5 years

Trial sites (71)

FacilityCityRegionStatus
Highlands Oncology Group, PA Fayetteville Arkansas
Highlands Oncology Group, PA Rogers Arkansas
Highlands Oncology Group, PA Springdale Arkansas
The Regents of the University of California Los Angeles California
UCLA Hematology/Oncology Los Angeles California
Moffitt Cancer Center Tampa Florida
MSK Basking Ridge Basking Ridge New Jersey
MSK Monmouth Middletown New Jersey
MSK Bergen Montvale New Jersey
MSK Commack Commack New York
MSK Westchester Harrison New York
Memorial Sloan Kettering Cancer Center (IDS Pharmacy) Long Island City New York
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). New York New York
Memorial Sloan Kettering Cancer Center 53rd street. New York New York
Memorial Sloan Kettering Cancer Center New York New York
MSK Nassau Uniondale New York
Hospital of the University of Pennsylvania Philadelphia Pennsylvania
The Trustees of the University of Pennsylvania, Clinical Research (OCR) Philadelphia Pennsylvania
The University of Texas MD Anderson Cancer Center Houston Texas
Fred Hutchinson Cancer Center Seattle Washington
Macquarie University North Ryde New South Wales
Mater Hospital Sydney Wollstonecraft New South Wales
Melanoma Institute Australia Wollstonecraft New South Wales
The Prince Charles Hospital Chermside Queensland
UZ Gent Ghent Oost-vlaanderen
Grand Hôpital de Charleroi Gilly Belgium
Cross Cancer Institute Edmonton Alberta
Kingston Health Sciences Centre-Kingston General Hospital Site Kingston Ontario
Aalborg Universitetshospital, Syd Aalborg North Denmark
Institut de Cancérologie de Lorraine Alexis Vautrin Vandœuvre-lès-Nancy Lorraine
Országos Onkológiai Intézet Budapest Hungary
Rabin Medical Center Petah Tikva Central District
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Lombardy
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Milano
IRCCS Istituto Clinico Humanitas Rozzano Milano
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Ancona Italy
Oita University Hospital Yufu Oita Prefecture
National Cancer Center Hospital Chuo-ku Tokyo
Japanese Foundation for Cancer Research Koto Tokyo
National Hospital Organization Kyushu Cancer Center Fukuoka Japan

+ 31 more sites — see the full list on the official registry below.

On this site

📄 Talzenna (talazoparib) drug profile → 📄 Inlyta (axitinib) drug profile →

More Pfizer trials in the USA

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) Active, not recruiting
Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants Active, not recruiting
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. Active, not recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies Recruiting

Other trials for the same condition

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Active, not recruiting
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer Active, not recruiting
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies Recruiting
Study of Oral MRT-2359 in Selected Cancer Patients Active, not recruiting
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05059522 on ClinicalTrials.gov ↗ ← All trials in the USA